Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.

Oncotarget - 10 Nov 2015

Sureban Sripathi M, Madhoun Mohammad F, May Randal, Qu Dongfeng, Ali Naushad, Fazili Javid, Weygant Nathaniel, Chandrakesan Parthasarathy, Ding Kai, Lightfoot Stanley A, Houchen Courtney W

Abstract excerpt

Tumor stem cell marker Doublecortin-like kinase1 (DCLK1) is upregulated in several solid tumors. The role of DCLK1 in hepatocellular carcinoma (HCC) is unclear. We immunostained tissues from human livers with HCC, cirrhosis controls (CC), and non-cirrhosis controls (NCC) for DCLK1. Western blot and ELISA analyses for DCLK1 were performed with stored plasma samples. We observed increased immunoreactive DCLK1 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Knockdown Techniques
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kruppel-Like Factor 4

Share to Liver Cirrhosis

Share to Mice, Nude

Share to Neoplastic Stem Cells

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26468984
DOI: 10.18632/oncotarget.5808
PMCID: PMC4741924

Genes

DCLK1
KLF4
NANOG
ZEB1
ZEB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.PMID 26468984Read ↗

Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expressionSemantic proximity Read ↗

Research Progress of DCLK1 Inhibitors as Cancer TherapeuticsSemantic proximity Read ↗

Pleiotropic effects of DCLK1 in cancer and cancer stem cellsSemantic proximity Read ↗

Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancerSemantic proximity Read ↗

Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem–like Cells Marked by DCLK1 KinaseSemantic proximity Read ↗

The kinase activity of the cancer stem cell marker DCLK1 drives gastric cancer progression by reprogramming the stromal tumor landscapeSemantic proximity Read ↗

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1Semantic proximity Read ↗

DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axisSemantic proximity Read ↗

DCLK1 induces a pro-tumorigenic phenotype to drive gastric cancer progression.Semantic proximity Read ↗

O‐GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/β‐catenin signallingSemantic proximity Read ↗

HBc Induces HCC Progression via lncRNA KCNQ1OT1/miR-335-5p/CDC7 AxisSemantic proximity Read ↗

MiRNA-205-5p Promotes Development of Hepatocellular Carcinoma Via Targeting DLC1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.